Follow
Mohamed Abou-el-Enein
Mohamed Abou-el-Enein
Keck School of Medicine USC
Verified email at med.usc.edu - Homepage
Title
Cited by
Cited by
Year
Immunogenicity of CAR T cells in cancer therapy
DL Wagner, E Fritsche, MA Pulsipher, N Ahmed, M Hamieh, M Hegde, ...
Nature reviews Clinical oncology 18 (6), 379-393, 2021
1632021
Overcoming challenges facing advanced therapies in the EU market
M Abou-El-Enein, A Elsanhoury, P Reinke
Cell Stem Cell 19 (3), 293-297, 2016
1522016
Concise review: a comprehensive analysis of reported adverse events in patients receiving unproven stem cell-based interventions
G Bauer, M Elsallab, M Abou-El-Enein
Stem cells translational medicine 7 (9), 676-685, 2018
1492018
Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion
L Amini, SK Silbert, SL Maude, LJ Nastoupil, CA Ramos, RJ Brentjens, ...
Nature Reviews Clinical Oncology 19 (5), 342-355, 2022
1482022
Regulatory T cells for minimising immune suppression in kidney transplantation: phase I/IIa clinical trial
A Roemhild, NM Otto, G Moll, M Abou-el-Enein, D Kaiser, G Bold, ...
bmj 371, 2020
1352020
Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy
M Abou-el-Enein, M Elsallab, SA Feldman, AD Fesnak, HE Heslop, ...
Blood cancer discovery 2 (5), 408-422, 2021
1132021
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours
CL Flugel, RG Majzner, G Krenciute, G Dotti, SR Riddell, DL Wagner, ...
Nature Reviews Clinical Oncology 20 (1), 49-62, 2023
1002023
Toward an optimized process for clinical manufacturing of CAR-Treg cell therapy
E Fritsche, HD Volk, P Reinke, M Abou-El-Enein
Trends in biotechnology 38 (10), 1099-1112, 2020
822020
Good Manufacturing Practices (GMP) manufacturing of advanced therapy medicinal products: a novel tailored model for optimizing performance and estimating costs
M Abou-El-Enein, A Römhild, D Kaiser, C Beier, G Bauer, HD Volk, ...
Cytotherapy 15 (3), 362-383, 2013
812013
CAR T-cell product performance in haematological malignancies before and after marketing authorisation
M Elsallab, BL Levine, AS Wayne, M Abou-El-Enein
The Lancet Oncology 21 (2), e104-e116, 2020
672020
Mitigating Deficiencies in Evidence during Regulatory Assessments of Advanced Therapies: A Comparative Study with Other Biologicals
M Elsallab, CA Bravery, A Kurtz, M Abou-El-Enein
Molecular Therapy. Methods & Clinical Development 18, 269, 2020
432020
Putting a price tag on novel autologous cellular therapies
M Abou-El-Enein, G Bauer, N Medcalf, HD Volk, P Reinke
Cytotherapy 18 (8), 1056-1061, 2016
422016
Telbivudine in chronic lymphocytic myocarditis and human parvovirus B19 transcriptional activity
S Van Linthout, A Elsanhoury, O Klein, M Sosnowski, K Miteva, D Lassner, ...
ESC heart failure 5 (5), 818-829, 2018
412018
COVID-19-induced ARDS is associated with decreased frequency of activated memory/effector T cells expressing CD11a++
M Anft, K Paniskaki, A Blazquez-Navarro, A Doevelaar, FS Seibert, ...
Molecular Therapy 28 (12), 2691-2702, 2020
392020
Strategies for derisking translational processes for biomedical technologies
M Abou-El-Enein, GN Duda, EA Gruskin, DW Grainger
Trends in biotechnology 35 (2), 100-108, 2017
382017
Cell and gene therapy trials: are we facing an ‘evidence crisis’?
M Abou-El-Enein, SP Hey
EClinicalMedicine 7, 13-14, 2019
352019
The business case for cell and gene therapies
M Abou-El-Enein, G Bauer, P Reinke
Nature Biotechnology 32 (12), 1192-1193, 2014
352014
Human genome editing in the clinic: new challenges in regulatory benefit-risk assessment
M Abou-El-Enein, T Cathomen, Z Ivics, CH June, M Renner, ...
Cell Stem Cell 21 (4), 427-430, 2017
342017
Registry contributions to strengthen cell and gene therapeutic evidence
M Abou-El-Enein, DW Grainger, S Kili
Molecular Therapy 26 (5), 1172-1176, 2018
302018
The human genome editing race: loosening regulatory standards for commercial advantage?
T Cathomen, S Schüle, M Schüßler-Lenz, M Abou-El-Enein
Trends in biotechnology 37 (2), 120-123, 2019
292019
The system can't perform the operation now. Try again later.
Articles 1–20